Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avacincaptad pegol - IVERIC bio

Next Previous
Drug Profile

Avacincaptad pegol - IVERIC bio

Alternative Names: Anti-C5 aptamer; ARC-1905; ASP-3021; Avacincaptad pegol sodium; IZERVAY; Zimura

Latest Information Update: 21 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Archemix Corporation
  • Developer IVERIC bio
  • Class Eye disorder therapies; Oligonucleotides; Polyethylene glycols
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dry age-related macular degeneration
  • Phase III Stargardt disease
  • Phase II Polypoidal choroidal vasculopathy; Wet age-related macular degeneration

Most Recent Events

  • 19 May 2025 Astellas Pharma plans a phase III trial for Dry age-related macular degeneration in Japan in May 2025 (Intravitreous, Injection) (NCT06970665)
  • 10 Apr 2025 Astellas Pharma completes a phase-III clinical trials in Dry age-related macular degeneration in USA, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czechia, France, Germany, Hungary, Israel, Italy, Latvia, Spain (Intravitreous) (NCT05536297)
  • 31 Mar 2025 Astellas Pharma completes a phase II trial in Stargardt disease in US, France, Germany, Hungary, Israel, Italy, Spain and the United Kingdom (Intravitreous)(NCT03364153)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top